Axe Compute Inc (NASDAQ:AGPU – Get Free Report) passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $6.78 and traded as low as $6.28. Axe Compute shares last traded at $6.41, with a volume of 236,041 shares trading hands.
Wall Street Analysts Forecast Growth
AGPU has been the topic of a number of research reports. JonesTrading raised shares of Axe Compute to a “strong-buy” rating in a research note on Saturday, September 26th. Wall Street Zen raised Axe Compute from a “sell” rating to a “hold” rating in a research report on Monday, August 24th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Axe Compute in a report on Thursday, August 27th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy”.
Check Out Our Latest Stock Analysis on Axe Compute
Axe Compute Price Performance
The firm’s 50 day moving average is $9.60 and its 200 day moving average is $6.78. The company has a market cap of $87.50 million, a PE ratio of -1.11 and a beta of 3.84.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Axe Compute stock. Goldman Sachs Group Inc. purchased a new position in Axe Compute Inc (NASDAQ:AGPU – Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 18,320 shares of the company’s stock, valued at approximately $208,000. Goldman Sachs Group Inc. owned 0.16% of Axe Compute as of its most recent SEC filing. Institutional investors and hedge funds own 9.04% of the company’s stock.
Axe Compute Company Profile
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation.
Further Reading
- Five stocks we like better than Axe Compute
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Axe Compute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axe Compute and related companies with MarketBeat.com's FREE daily email newsletter.
